Company Overview and News


Add CLNV
to your dashboard

Headline News

Cellnovo Acquires Commercial License for Artificial Pancreas Technology from TypeZero Technologies

2017-04-19 accesswire
PARIS, FRANCE and CHARLOTTESVILLE, VA / ACCESSWIRE / April 18, 2017 / Cellnovo Group ("Cellnovo" EN Paris: CLNV), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero's Artificial Pancreas (AP) technology into Cellnovo's mobile diabetes management system.